CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
CervoMed Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.31+0.07 (+3.12%)
Close on Oct 19, 2026
- Market cap
- $23.66M
- P/E (TTM)
- –
- Dividend yield
- –
CervoMed Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q2 25 | Q3 14 | Q2 14 | Q1 14 | Q4 13 | Q3 13 | Q2 13 | Q1 13 | Q4 12 | Q3 12 | Q2 12 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single Reportable Segments [Member] | $0 | $1.76M | – | – | – | – | – | – | – | – | – | – | – | -100.0% |
| ProElite | – | – | – | – | – | $0 | $0 | $0 | $72 | $0 | $144 | $71 | – | – |
| Total | – | – | – | – | – | $0 | $0 | $0 | $72 | $0 | $144 | $71 | – | – |
| Operating income | Q2 26 | Q2 25 | Q3 14 | Q2 14 | Q1 14 | Q4 13 | Q3 13 | Q2 13 | Q1 13 | Q4 12 | Q3 12 | Q2 12 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other [Member] | – | – | – | – | -$477.00K | -$562 | -$8 | $8.98K | -$9.00K | -$4 | -$8 | -$10 | – |
| ProElite | – | – | – | – | – | -$2 | $0 | $0 | $72 | $0 | $141 | $65 | – |
| Total | – | – | – | – | -$478.00K | -$651 | -$8 | $9.06K | -$9.00K | -$4 | $133 | $55 | – |
| Total [Member] | – | – | – | – | – | – | – | – | – | – | -$4 | – | – |
| Bio Pharma | – | – | – | – | -$1.00K | – | – | – | – | – | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of CervoMed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.